Top Abstract Purchase Related
Home
>
Node
>
Subnode

Leukotriene B4: an inflammatory mediator with vascular actions in vivo

Bray, M.A.

Agents and Actions. Supplements 11: 51-61

1982

ISSN/ISBN: 0379-0363
PMID: 6295113
Document Number: 192819
Leukotriene B4 (LTB4) is a 5, 12-dihydroxy derivative of arachidonic acid generated by a variety of inflammatory cells via the lipoxygenase enzyme system. In vitro leukotriene B4 is a potent chemotactic and aggregatory agent; enhances neutrophil complement receptors; stimulates membrane calcium changes and causes contraction of lung parenchyma. In vivo LTB4 is a potent stimulator of vascular permeability in rats, rabbits, guinea-pigs and man particularly in the presence of a vasodilator such as PGE2. LTB4 causes a profound transient neutropenia and massive accumulation of neutrophils when injected into the dermis (rabbit and man), skin chambers (rabbit and man) or body cavities (guinea-pig, rat).

Document emailed within 1 workday
Secure & encrypted payments

Aoyagi, T.; Wada, T.; Ohuchi, S.; Kawamura, K.; Fukatsu, S.; Umezawa, H. 1984: In vivo actions of bestatin-related compounds in relation to their actions in vitro Biochemistry International 9(5): 643-650
Page, C.P.; Archer, C.B.; Guerreiro, D.; Morley, J. 1985: Properties of PAF-acether appropriate to a mediator of the inflammatory aspects of asthma International Journal of Tissue Reactions 7(5): 351-354
Iwaszkiewicz, K.S.; Hua, S. 2014: Development of an effective topical liposomal formulation for localized analgesia and anti-inflammatory actions in the Complete Freund's Adjuvant rodent model of acute inflammatory pain Pain Physician 17(6): E719-E735
Stewart, D.J. 1990: Endothelin-1--marker or mediator of vascular disease? Canadian Journal of Cardiology 6(8): Viii
Wakefield, T.W.; Greenfield, L.J.; Rolfe, M.W.; DeLucia, A.; Strieter, R.M.; Abrams, G.D.; Kunkel, S.L.; Esmon, C.T.; Wrobleski, S.K.; Kadell, A.M. 1993: Inflammatory and procoagulant mediator interactions in an experimental baboon model of venous thrombosis Thrombosis and Haemostasis 69(2): 164-172
Harvey, E.H.; Tyburski, J.G.; Steffes, C.P.; Carlin, A.M. 2004: Inhibition of heme oxygenase-1 in microvascular lung pericytes diminishes at high concentrations of an inflammatory mediator American Surgeon 70(2): 141-145; Discussion 145
Takematsu, H.; Terui, T.; Tagami, H. 1986: Demonstration of leukotriene B4 in the scale extracts of psoriasis and inflammatory pustular dermatoses. Correlation with leukocyte chemotactic activity and C5a anaphylatoxin Acta Dermato-Venereologica 66(1): 6-10
Baumeister, B.; Schmidt, C.; Helisch, A.; Kipnowski, J. 1996: Increased prostaglandin E2 and leukotriene B4 synthesis in isolated colonic mucosal cells in inflammatory bowel disease. a preliminary report Journal of Clinical Gastroenterology 22(2): 117-120
Thien, F.C.; Hallsworth, M.P.; Soh, C.; Lee, T.H. 1993: Effects of exogenous eicosapentaenoic acid on generation of leukotriene C4 and leukotriene C5 by calcium ionophore-activated human eosinophils in vitro Journal of Immunology 150(8 Part 1): 3546-3552
Nielsen, O.H.; Elmgreen, J.; Thomsen, B.S.; Ahnfelt-Rønne, I.; Wiik, A. 1986: Release of leukotriene B4 and 5-hydroxyeicosatetraenoic acid during phagocytosis of artificial immune complexes by peripheral neutrophils in chronic inflammatory bowel disease Clinical and Experimental Immunology 65(2): 465-471
Levi-Schaffer, F.; Dayton, E.T.; Austen, K.F.; Hein, A.; Caulfield, J.P.; Gravallese, P.M.; Liu, F.T.; Stevens, R.L. 1987: Mouse bone marrow-derived mast cells cocultured with fibroblasts. Morphology and stimulation-induced release of histamine, leukotriene B4, leukotriene C4, and prostaglandin D2 Journal of Immunology 139(10): 3431-3441
Mong, S.; Wu, H.L.; Miller, J.; Hall, R.F.; Gleason, J.G.; Crooke, S.T. 1987: SKF 104353, a high affinity antagonist for human and guinea pig lung leukotriene D4 receptor, blocked phosphatidylinositol metabolism and thromboxane synthesis induced by leukotriene D4 Molecular Pharmacology 32(1): 223-229
Blantz, R.C.; Pelayo, J.C. 1983: In vivo actions of angiotensin Ii on glomerular function Federation Proceedings 42(14): 3071-3074
Feigen, L.P. 1981: Actions of prostaglandins in peripheral vascular beds Federation Proceedings 40(7): 1987-1990
Ledderhos, C.; Mattson, D.L.; Skelton, M.M.; Cowley, A.W. 1995: In vivo diuretic actions of renal vasopressin V1 receptor stimulation in rats American Journal of Physiology 268(3 Pt 2): R796-R807
Bagdy, G. 1996: Studies on the sites and mechanisms of 5-HT1A receptor-mediated in vivo actions Acta Physiologica Hungarica 84(4): 399-401
Ballerini, P.; Di Iorio, P.; Ciccarelli, R.; Caciagli, F.; Poli, A.; Beraudi, A.; Buccella, S.; D'Alimonte, I.; D'Auro, M.; Nargi, E.; Patricelli, P.; Visini, D.; Traversa, U. 2005: P2Y1 and cysteinyl leukotriene receptors mediate purine and cysteinyl leukotriene co-release in primary cultures of rat microglia International Journal of Immunopathology and Pharmacology 18(2): 255-268
Hyman, A.L.; Kadowitz, P.J. 1980: Vasodilator actions of prostaglandin 6-keto-E1 in the pulmonary vascular bed Journal of Pharmacology and Experimental Therapeutics 213(3): 468-472
Altura, B.M.; Altura, B.T. 1983: Peripheral vascular actions of ethanol and its interaction with neurohumoral substances Neurobehavioral Toxicology and Teratology 5(2): 211-220
Fernández-Gallardo, S.; Ortega, M.P.; Priego, J.G.; de Casa-Juana, M.F.; Sunkel, C.; Sánchez Crespo, M. 1990: Pharmacological actions of PCA 4248, a new platelet-activating factor receptor antagonist: in vivo studies Journal of Pharmacology and Experimental Therapeutics 255(1): 34-39